CYP1A2genetic polymorphisms are associated with treatment response to the antidepressant paroxetine

Pharmacogenetics of antidepressive treatment

(2010) Astrid Zobel et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Response and remission criteria in major depression – A validation of current practice

(2010) Michael Riedel et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

(2010) Ming-Hsien Tsai et al.   PHARMACOGENOMICS

Patients with depressive disorder, their co-morbidity, visiting rate and disability in relation to self-evaluation of physical and mental health: a cross-sectional study in family practice

(2009) Kadri Suija et al.   BMC Family Practice

Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-Based Simulator

(2009) J. Jornil et al.   DRUG METABOLISM AND DISPOSITION

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

(2009) Alessandro Serretti et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Pharmacogenetics of anxiolytic drugs

(2009) Arun K. Tiwari et al.   JOURNAL OF NEURAL TRANSMISSION

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome

(2009) B Laika et al.   PHARMACOGENOMICS JOURNAL

Paroxetine

(2008) Siu Wa Tang et al.   EXPERT OPINION ON PHARMACOTHERAPY

A multifactorial developmental model for the etiology of Major Depression in a population-based sample

(2008) Louise Sjöholm et al.   JOURNAL OF AFFECTIVE DISORDERS

Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression

(2008) Manfred Uhr et al.   NEURON

Meta-analysis of Major Depressive Disorder Relapse and Recurrence With Second-Generation Antidepressants

(2008) R. Hansen et al.   PSYCHIATRIC SERVICES

A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

(2008) Hikaru Hori et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY